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Structured Abstract 45 
Background 46 
Prevention of sexually transmitted infection (STI) incidence in England is a high priority, 47 
particularly among young people, men who have sex with men (MSM) and black ethnic 48 
minorities. An economic evaluation of condom distribution programs (CDPs) to reduce STI 49 
transmission is presented. 50 
Methods 51 
An economic model using a Bernoulli Process estimated the number of people acquiring an 52 
STI as a function of its prevalence, transmission rate, condom use, condom failure rate, and 53 
number of sexual contacts. Models were developed for young people (13-24 years), black 54 
ethnic minorities, MSM and the general English population. Effectiveness evidence came 55 
from a recent systematic review. For young people, a CDP was modelled (relative risk for 56 
condom use=1.23), along with an exploratory analysis of the impact on unintended 57 
pregnancies. For other populations, threshold analyses were used to identify the 58 
combination of costs and effect-size required to make a program cost-effective. 59 
Results 60 
The base case predicted that CDP for all young people in England could avert 5,123 STI 61 
cases per annum, with an incremental cost-effectiveness ratio of £17,411. In addition, it 62 
could avert 118 pregnancies and 82 abortions and save £333,000 in associated costs. 63 
Schemes for black ethnic minorities and MSM could also be cost-effective even with 64 
relatively high costs and small effect-sizes.  65 
Conclusion  66 
CDPs for young people are likely to be cost-effective or cost-saving. CDPS for other high-67 
risk populations may also be cost-effective if they can increase condom use, since high HIV 68 
prevalence in these groups imposes a considerable health and cost burden. 69 
  70 
Thumbnail Sketch  71 
What is already known on this subject? 72 
435,000 sexually transmitted infections were diagnosed in England in 2015, with substantial 73 
year-on-year increases in syphilis and gonorrhoea. Incidence was particularly high in young 74 
people under the age of 25, men who have sex with men and black ethnic minorities. 75 
Condom distribution programs provide condoms free or at reduced prices, sometimes with 76 
training or support, to try and increase condom use and prevent the spread of sexually 77 
transmitted infections. 78 
A recent systematic literature review highlighted a paucity of relevant evidence evaluating 79 
the cost-effectiveness of condom distribution programs in the UK.  80 
 81 
What this study adds? 82 
An economic model to evaluate the cost-effectiveness of condom distribution programs was 83 
developed. It suggested that an intervention which provides free condoms along with some 84 
education and support to young people in England could be expected to avert 5,123 new 85 
sexually transmitted infections per annum. This would lead to improved health-related quality 86 
of life and treatment cost savings, resulting in an estimated incremental cost of £17,411 per 87 
quality-adjusted life-year gained compared with no program.  88 
Condom distribution programs for men who have sex with men and black ethnic minorities 89 
may also be cost-effective even with small increases in condom use since these groups 90 
have higher prevalence of HIV, which has a big impact on life-expectancy, quality of life and 91 
treatment costs. 92 
  93 
Introduction 94 
Sexually transmitted infections (STIs) have detrimental impacts on quality of life and survival 95 
and impose a burden on the UK National Health Service (NHS). In 2015 there were 435,000 96 
new diagnoses in England with a 20% and 11% increase observed in the incidence of 97 
syphilis and gonorrhoea respectively compared with 2014 (2). STI incidence is highest 98 
among people under the age of 25, men who have sex with men (MSM) and black ethnic 99 
minorities (2).  100 
Condoms can protect against transmission of many STIs including gonorrhoea, chlamydia, 101 
syphilis and HIV (3). The 2014-15 increase in syphilis and gonorrhoea diagnoses is 102 
attributed to high levels of unprotected sex (2). Reasons condoms are not used or are used 103 
incorrectly include cost, lack of knowledge and social norms. Condom distribution programs 104 
(CDPS) aim to overcome these challenges by providing condoms free of charge or at 105 
reduced prices, possibly accompanied by training or support, such as the C-Card program 106 
(the multi-component program most commonly offered to young people in England) (4).  107 
7KH'HSDUWPHQWRI+HDOWKUHIHUUHGWKHWRSLF³6H[XDOO\WUDQVPLWWHGLQIHFWLRQVFRQGRP108 
GLVWULEXWLRQVFKHPHV´WRWKH1DWLRQDO,QVWLWXWHIRU+HDOWKDQG&DUH([FHOOHQFH1,&(WR109 
develop public health guidance (5).. NICE considers evidence for effectiveness and cost-110 
effectiveness in developing recommendations. A systematic literature review highlighted a 111 
paucity of evidence for the cost-effectiveness of condom distribution programs in the UK (6). 112 
Therefore, we developed an economic model to evaluate the cost-effectiveness of CDPs. 113 
This study presents our economic evaluation of CDPs for the general population and for 114 
targeted at-risk groups: young people, MSM, and black ethnic minorities.  115 
  116 
Methods 117 
Population 118 
We based the population on English 2011 census data by gender and five-year age-group 119 
(7). Cohorts of the appropriate age-range and gender were selected to model each of the 120 
target groups. 121 
Model 122 
We developed an economic model which estimated µVWHDG\VWDWH¶67,DFTXLVLWLRQDQG 123 
associated cost-effectiveness. The model uses an established Bernoulli Process which 124 
estimates the number of STIs in a cohort of people (8) and has been used in other economic 125 
evaluations, including NICE Public Health guidelines (10, 11). The model predicts the 126 
proportion of people acquiring an STI in a given gender- and age-specific group ሺܹሻ as a 127 
function of the STI prevalence (ݒ), the proportion of sexually active people using condoms 128 
(݃), the STI transmission rate (ݐ), the condom failure rate (݇ሻ, and the annual number of 129 
sexual contacts in that subgroup (ݏሻ: 130 
ܹ ൌ ݒሺቀ݃൫ ? െሺሺ ? െݐ݇ሻ௦ሻ൯ቁ ൅ ቀሺ ? െ ሻ݃൫ ? െሺሺ ? െ ݐሻ௦ሻ൯ቁሻ 
The impact of a CDP was captured by changing the proportion of people using condoms (݃) 131 
according to the effectiveness of the intervention while all other parameters were held 132 
constant. Outputs were total STI cases averted, quality-adjusted life years (QALYs)gained, 133 
costs and cost-effectiveness (cost per QALY gained).  134 
 135 
Effectiveness 136 
NICE¶V systematic review searched for evidence of effectiveness, in terms of changing 137 
condom use, of single-component programs (free provision of condoms), multi-component 138 
programs (provision of condoms along with some sort of education or advice element) and 139 
cost-price condom provision programs between 1996 and 2015 (6) and identified 20 studies. 140 
Three studies were of multi-component programs in young people. These reported relative 141 
risks of 1.11 (95% CI=0.94-1.32) for condom use at last intercourse (Furstenberg et al. (12)), 142 
1.13 (1.04-1.22) for condom use at last intercourse (Guttmacher et al. (13)) and 1.23 (1.10-143 
1.38) for ever having used a condom (Larsson et al. (14)). Evidence quality varied, with 144 
Furstenberg et al. and Guttmacher et al. reporting quasi-experimental and pre-and post- 145 
intervention evaluations, whereas Larsson et al. reported a controlled trial. The studies were 146 
located in the US (Furstenberg, Guttmacher) and Sweden (Larsson). No studies evaluated 147 
interventions in the UK. The review concluded that there was some limited evidence to show 148 
that multi-component programs in high schools can increase condom use. The highest 149 
quality study (14) was chosen to give the estimated effectiveness in the base case (also the 150 
study with the largest effect size). It is worth noting that the population (students aged 17) 151 
and intervention (school-based) used in this trial was not a perfect match for the C-card 152 
program, which targets a broader age-range (typically ages 13-24) and in a wider range of 153 
settings (including sexual health, genito-urinary medicine clinics, youth services and 154 
schools). The base case uses an age range of 13-24 to replicate C-card. However, since the 155 
evidence is taken from a younger population, a scenario for ages 13-18 years is also 156 
presented. 157 
The review identified one study targeting black ethnic minorities (15). This study was located 158 
in the USA and targeted those with high levels of syphilis. It reported that condom use 159 
increased, although study quality was poor and data were not presented. 160 
The review identified one single component program targeting MSM. However, this study did 161 
not ask about condom use at last anal intercourse and despite improvements in condom 162 
possession rate, a small increase in men saying WKH\µKDGDQDOLQWHUFRXUVHZLWKRXWD163 
FRQGRPVLPSO\EHFDXVHWKHUHZDVQRFRQGRPDYDLODEOH¶ was reported (16). 164 
The review identified only one study looking at reduced-price condom provision (17). 165 
Although this study showed increased condom purchasing, no data were collected on 166 
condom use.  167 
Due to the lack of effectiveness evidence for programs for black ethnic minorities, MSM and 168 
the general population via discounted provision, a threshold analysis was carried out for 169 
these groups assessing a range of effectiveness and cost levels, to identify the combination 170 
of costs and effectiveness required to make a program cost effective at a threshold of 171 
£20,000 per QALY gained, or dominant (QALY-improving and cost-saving). £20,000 per 172 
QALY is the notional threshold used by NICE to assess whether interventions are 173 
considered cost-effective if funded by the NHS. 174 
QALYs 175 
QALY loss was modelled either using an absolute QALY reduction per STI obtained from the 176 
literature or a disutility per STI multiplied by time affected. For HIV Farnham et al. (18) was 177 
used, assuming people were diagnosed when their  CD4 count was above 500, and 178 
including QALYs lost due to infections and reduced life-expectancy, with a 3% annual 179 
discounted rate, this being a US study. All QALY decrements are shown in Table 1. 180 
[INSERT TABLE 1] 181 
STIs 182 
The STIs modelled are chlamydia, gonorrhoea, syphilis, human immunodeficiency virus 183 
(HIV) and pelvic inflammatory disease (PID), which can follow chlamydia or gonorrhoea in 184 
women. Prevalence of chlamydia, gonorrhoea and syphilis by risk group, age and gender 185 
were taken from Public Health England (PHE) cases in 2014 (19). HIV prevalence was 186 
based on new cases from PHE (20). Prevalence estimates are shown in Table 1. 187 
[INSERT TABLE 2] 188 
Other parameters 189 
Table 1 contains all the parameters of the STI model. Age and gender-specific proportions of 190 
people who are sexually active and rates of sexual contact were taken from Mercer et al. 191 
(21), with under-13s assumed not to be sexually active. The percentage of men who are 192 
MSM (2.8%) was taken from the National Survey of Sexual Attitudes and Lifestyles (22). 193 
Age-specific rates of routine condom use for young people, black ethnic minorities and the 194 
general population were reported by the Office of National Statistics (20), with under-16s 195 
assumed the same as 16-19 year-olds. MSM condom use was taken from the 2008 UK Gay 196 
0HQ¶V6Hx Survey (23) and applied across all ages. Condom failure rate was based on 197 
Macaluso et al. (24).  198 
Evidence on the probability of transmission per unprotected sexual contact is old and limited 199 
by the ethical implications of this research. Rates and sources are presented in Table 1. 200 
Rates of PID as a function of the number of cases of chlamydia and gonorrhoea were based 201 
on two studies (25, 26). 202 
 203 
Costs 204 
We used an NHS and personal social services perspective, a cost year of 2015 and a 3.5% 205 
annual discount rate. All costs are shown in Table 1. We include in STI treatment costs the 206 
appropriate number of consultations, tests and treatments using the British National 207 
Formulary (BNF) (27) and unit costs of health and social care (28). Costs of PID were taken 208 
from a previously published report. (11). The UK lifetime HIV treatment cost was taken from 209 
Nakagawa et al, (29) using the more conservative of their two estimates (based on the 210 
assumption of switching to generic drugs once pharmaceutical patents expire, and assuming 211 
generic drugs cost 20% of the branded versions). It was thought important to use the more 212 
conservative estimate here to avoid potentially overestimating the costs. 213 
A rapid search identified intervention costs for five local C-card programs in England and 214 
Wales (30-34). Using published population statistics for ages 13-24 for each area (7), we 215 
calculated that four of the five programs gave costs between £0.33 and £0.68 per head of 216 
teenage population per annum (the other had higher costs of £1.21 per head). An estimated 217 
cost of £0.48 (95% CI=£0.19-£0.76) per head of teenage population was chosen as the 218 
average of the four lowest-cost published programs. This cost was validated using a bottom-219 
up costing exercise informed by experts with experience of running programs. 220 
 221 
Uncertainty 222 
A probabilistic sensitivity analysis (PSA) of 5,000 runs was conducted to assess the impact 223 
of parameter uncertainty on the model output. All results presented are probabilistic.  224 
The systematic review identified three studies of multicomponent programs in young people. 225 
In our base case we used the highest-quality study, but this also had the largest effect size 226 
(RR=1.23). As a sensitivity analysis we calculated the incremental cost effectiveness ratio 227 
(ICER) associated with a condom use relative risk of 1.11 (the lower effect size from the 228 
three studies). 229 
There is reasonable evidence in the literature that condom failure rates reduce with 230 
experience (35). A scenario was modelled for young people which assumed reduced 231 
condom breakage (odds ratio of 0.8) based on Macaluso et al. (24). 232 
Base-case HIV prevalence estimates are from diagnosis rates and may underestimate the 233 
true prevalence of HIV. Therefore, higher HIV prevalence scenarios were modelled using 234 
estimated HIV prevalence by risk group from the 2015 HIV Situation Report (36) and in 235 
addition using updated figures for MSM in London (20). In the general population a scenario 236 
used rates from the NICE HIV testing guideline (10). 237 
To validate our model we compared our results for young people, with and without a CDP, to 238 
the 2014-2015 PHE data for STI prevalence (37). 239 
7KHIRFXVRI1,&(¶VJXLGHOLQHZDV67,V+RZHYHU, an exploratory analysis was undertaken, 240 
to understand the impact of the interventions in young people aged of 14±18 years upon 241 
pregnancy, using an existing model of contraceptive interventions (38) and assuming that all 242 
pregnancies within this age group were unintended. It was assumed that 50% of the 243 
unintended teenage pregnancies would be prevented and 50% delayed until age 19-24. The 244 
probability of becoming pregnant and of having an abortion by age were updated using the 245 
latest national statistics (39). The model was updated to use the same condom failure rate 246 
as the STI model. Costs were expressed in 2014/15 prices (40). 247 
  248 
Results 249 
Results for young people aged 13-24 are summarised in Table 3. The analysis predicts that 250 
an intervention with effectiveness taken from Larsson et al. (14) and with costs in the region 251 
of a typical C-card program would be expected to avert 5,123 cases of STIs (95% CI=439-252 
12,441), of which over 4,200 (30,655-85,406) are chlamydia. The program is estimated to 253 
lead to a gain of 55 (14-136) QALYs and a positive net cost (program cost minus healthcare 254 
savings) of £957,622 (-£2,723,496-£2,947,501), giving an incremental cost per QALY gained 255 
of £17,411 compared with no CDP.  256 
The evidence for effectiveness was for a younger age group, however. With age 13-18 years 257 
only, the program was not cost-effective at 1,&(¶V £20,000 level (ICER = £45,856).  258 
The result was sensitive to reducing the effectiveness estimate. With a reduced change in 259 
condom use (R=1.11), the ICER in the 13-24 age group increased to £88,979. The results of 260 
the scenario analysis where condom breakage was reduced led to an ICER of £14,469. In 261 
the scenario with higher HIV prevalence the increase in HIV cases averted makes the 262 
program cost-saving overall (£10m healthcare savings compared with £3.5m program costs 263 
across England in the target population). 264 
[INSERT TABLE 3] 265 
In an additional exploratory analysis of pregnancy outcomes, an England-wide program with 266 
base case costs and effectiveness is predicted to avoid approximately 118 pregnancies, 82 267 
abortions and save £333,000 across England in associated costs (not included in our 268 
presented results). This would increase to £12m if government funded benefits were 269 
included. 270 
Figure 1 illustrates the results of threshold analyses for the base case in each population. 271 
The result show that CDPs are much more likely to be cost-effective in populations with high 272 
prevalence of HIV (MSM and black ethnic minorities), and that even programs with relatively 273 
small effect sizes and high costs can be cost-saving in these groups. Meanwhile, programs 274 
for young people can be cost-effective or cost-saving as long as costs can be controlled to 275 
around 40-60p per person, depending on effectiveness. Untargeted programs for the general 276 
population are only likely to be cost-effective at very low cost. 277 
[INSERT FIGURE 1] 278 
Results of model validation are shown in Figure 2. The model correctly shows a decrease in 279 
chlamydia diagnoses, although it overestimates this decrease by approximately 40%. 280 
Similarly the model overestimates the decrease in gonorrhoea diagnoses, which actually 281 
increased among 20-24 year old males. Syphilis remains fairly constant in both the model 282 
and PHE data, except the model shows a small decrease in cases for 20-24 year old males 283 
and PHE data shows an increase. 284 
[INSERT FIGURE 2] 285 
  286 
Discussion 287 
The cost-effectiveness of CDPs is heavily influenced by the underlying STI prevalence and 288 
sexual activity levels of the population.  289 
We found that the ICER for CDP targeted at young people, such as the C-Card program was 290 
likely to be cost-effective at 1,&(¶V£20,000/QALY threshold. Threshold analyses suggest 291 
that CDPs for MSM and black ethnic minorities can also be cost-effective even if the 292 
program cost per person is fairly high, whereas for the general population in which 293 
prevalence and risk of transmission are lower, costs have to be very low in order for 294 
programs to be cost-effective.  295 
HIV prevalence is particularly important in determining cost-effectiveness. This is because 296 
although HIV is relatively less prevalent than other STIs, the cost and QALY loss per case is 297 
much higher. Our study confirms findings (41, 42) that CDPs for populations with high HIV 298 
prevalence can be cost-effective when condom usage is increased by as little as 2% 299 
(RR=1.02). 300 
$OWKRXJKWKHIRFXVRI1,&(¶VJXLGance was STI prevention, our analysis suggests that 301 
including the potential impact on reduced conception rates makes it very likely that a CDP 302 
would be cost-saving. This analysis was somewhat speculative, especially in terms of 303 
government-funded benefit costs, since the benefits landscape has changed considerably 304 
since the original model was developed in 2010.  305 
This is the first study to estimate the cost-effectiveness of CDPs in the UK. It combines data 306 
from several different sources, and gives an indication of the potential economic impact of C-307 
Card programs which has not previously been reported. However, the analysis is limited by 308 
the quality and availability of evidence. It assumes that all sexually active people within one 309 
age band behave in the same way, with an average number of sexual contacts and the 310 
same probability of condom use without a CDP. In reality there will be some people who are 311 
more sexually active than others, some people in monogamous relationships and some with 312 
higher numbers of sexual partners, and condom usage rates will differ according to these 313 
(and other) factors. 314 
Validating the binomial model of disease prevalence is challenging because the current 315 
distribution and uptake of CDPs in England are unknown, and because CDPs are often 316 
linked to other services such as STI testing which impact diagnosis rates and confound 317 
prevalence estimates. We expected the model results without CDP to show more STIs than 318 
the PHE 2015 data, and the model results with CDP to show fewer STIs than the PHE 2015, 319 
since in reality a number of CDPs programs are already in operation. We saw that for all 320 
STIs, the model results with and without STIs were lower than the PHE data. The binomial 321 
model of steady state disease prevalence appears therefore to underestimate STI 322 
transmission and therefore potentially underestimates the effect of increased condom usage 323 
on STI reduction, which suggests that the estimates of CDP cost-effectiveness are likely to 324 
be conservative.  325 
We used a static model for estimating the transmission of STIs, assuming a constant 326 
underlying prevalence of each STI. In reality, for STIs with long recovery periods or no 327 
recovery, the underlying prevalence will increase. This may partly explain why our model 328 
under-predicts STI prevalence. This effect may be particularly important in the case of HIV, 329 
for which both costs and quality of life effects are high. In addition, our model does not take 330 
account of the potential transmission of infections such as HIV and syphilis from mother to 331 
baby, where condom use before and during pregnancy may have the additional impact of 332 
reducing infection or other severe health impacts on foetuses or new-borns.  333 
Our model was not able to account for any effects of increased condom use on undiagnosed 334 
STIs. There may also be variability around CDP costs. We used the average from four C-335 
Card programs with similar costs as these closely corresponded to a bottom-up costing 336 
exercise, and excluded one program that had higher costs.  337 
Our model considers STI transmission over a one-year period, which may underestimate the 338 
benefit of CDPs for two reasons. Firstly, since new STI diagnoses are a function of initial 339 
prevalence, the rates of new diagnoses for CDP and a comparator without CDP, diagnoses 340 
would be expected to diverge over time and the incremental effectiveness would increase. 341 
Secondly, there may be longer term benefits of engaging people with CDPs and sexual 342 
health services, potentially resulting in fewer STIs at little or no extra cost. 343 
More research of better quality is needed on the effectiveness of CDPs. Research that 344 
investigates change in condom usage would also allow the economic models to be updated, 345 
while research investigating the relationship between CDP implementation and STI 346 
incidence would remove the need for an epidemiological model. Evaluations of C-Card 347 
programs are particularly important to understand both their effectiveness and cost-348 
effectiveness. Furthermore, comparative evaluation of different modes of implementation of 349 
C-Card programs and different population subgroups or age groups would allow policy 350 
makers to understand how these programs may be optimally delivered and targeted. 351 
We conclude that CDPs for young people are likely to be good value for money at currently 352 
accepted cost-effectiveness thresholds, and that CDPs for other high-risk populations may 353 
also be economically attractive. Given the substantial public health burden associated with 354 
STIs, it is important that efforts are made to reduce their transmission and this suggests that 355 
CDPs are likely to be a cost-effective approach. 356 
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  370 
Tables/Illustrations:  371 
Table 1 Costs (£), QALYs and STI transmission parameters and distributions used in the 372 
model 373 
 Mean Range Source 
COSTS (£) DIAGNOSIS AND TREATMENT  
Chlamydia 121.92 Max = 75.76 Min = 166.58 (28) (44) 
(45) 
Gonorrhoea 206.17 Max = 129.24 Min = 280.61 (28) (44) 
(45) 
Syphilis 210.59 Max = 133.66 Min = 285.03 (28) (44) 
(45) 
HIV 103,243 95% CI = 82,594 - 123,892 (29) 
PID 3,124 95% CI = 2499 - 3749 (11) (28) 
COSTS (£) INTERVENTION 
C-card per head (age 13-24) 0.48 95% CI = 0.34 - 0.62 (30, 32-34) 
QALYs  
Chlamydia -0.002 - (46)  
Gonorrhoea -0.004 - (46)  
HIV -6.200 95% CI = -7.950 - -4.450 (18)  
Syphilis -0.006 95% CI = -0.0068 - -0.0055 (47)  
PID -0.025 - (48)  
Parameter Value Distribution 
Įȕ5RXQGHG 
(unless specified) 
Source 
SEXUAL PRACTICE ± CONDOM USE (By age) 
16-19 
20-24 
25-29 
30-34 
35-39 
40-44 
45-49 
54% 
54% 
41% 
46% 
27% 
10% 
13% 
None 
 
(49) 
(49) 
(49) 
(49) 
(49) 
(49) 
(49)  
MSM (All ages) 52.7% (23) 
CONDOM BREAKAGE 
Rate 3.6% Beta (194, 9,704) (24)  
SEXUALLY ACTIVE ± MEN 
13 
14 
15 
4.4% 
11.8% 
26.0% 
 NATSAL-3 
dataset (21)  
(21) 
(21) 
(21) 
(21) 
(21) 
(21) 
(21) 
16-24 
25-34 
35-44 
45-54 
55-64 
65- 
75.9% 
90.1% 
92.5% 
86.4% 
76.3% 
59.8% 
Beta (1,007, 320) 
Beta (952, 105) 
Beta (682, 55) 
Beta (68, 11) 
Beta (533, 166) 
Beta (336, 226) 
SEXUALLY ACTIVE ± WOMEN 
13 
14 
15 
2.3% 
8.5% 
21.4% 
 NATSAL-3 
dataset (21) 
(21) 
16-24 
25-34 
77.0% 
91.8% 
Beta (1,246, 372) 
Beta (1,698, 152) 
(21) 
(21) 
35-44 
45-54 
55-64 
65- 
90.8% 
85.0% 
63.7% 
42.1% 
Beta (850, 86) 
Beta (990, 175) 
Beta (519, 296) 
Beta (266, 365) 
(21)  
(21)  
(21)  
(21)   
SEXUAL CONTACTS ± MEN 
13-15 5.10  Gamma (0.50, 10.16) assumed 
16-24 
25-34 
35-44 
45-54 
55-64 
65- 
5.10  
 5.40  
 4.10  
 4.10  
 3.20  
 2.30 
Gamma (0.50, 10.16) 
Gamma (0.69, 7.82) 
Gamma (0.91, 4.51) 
Gamma (0.45, 9.08) 
Gamma (0.51, 6.33) 
Gamma (0.41, 5.63) 
(21)  
(21) 
(21) 
(21) 
(21) 
(21) 
SEXUAL CONTACT ± WOMEN 
13-15 5.80  Gamma (0.77, 7.51) assumed 
16-24 
25-34 
35-44 
45-54 
55-64 
65- 
5.80  
 4.90  
 4.00  
 3.50  
 2.50  
 1.40 
Gamma (0.77, 7.51) 
Gamma (0.92, 5.31) 
Gamma (0.76, 5.29) 
Gamma (0.69, 5.04) 
Gamma (0.54, 4.62) 
Gamma (0.37, 3.78) 
(21)  
(21) 
(21) 
(21) 
(21) 
(21) 
PID RATES  
after chlamydia 
after gonorrhoea 
16.0% 
0.9% 
Beta (9, 47) 
Beta (4, 469) 
(25)  
(50)  
TRANSMISSION RATES 
HIV ± Men 
HIV - MSM 
HIV ± Women 
0.120% 
1.400% 
0.390% 
Beta (10, 8,175) 
Beta (6, 394) 
Beta (5, 1,324) 
(51)  
(52) 
(51) 
Chlamydia 45.000% Beta (42, 52) (53)  
Gonorrhoea 53.000% Beta (16, 14) (53)  
Syphilis 61.818% Beta (68, 42) (54)  
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Table 2: Mean prevalence values used in the model for Chlamydia, Gonorrhoea, HIV & Syphilis  
Age 
group 
Chlamydia Gonorrhoea HIV Syphilis 
Low (Base 
case) 
Central High 
  
 Male Female Male Female Male Female Male Female Male Female Male Female 
YOUNG PEOPLE & GENERAL POPULATION 
13 ± 14 0.009% 0.136% 0.001% 0.010% 0.004% 0.001% - - 0.054% 0.019% 0.000% 0.000% 
15 ± 19 0.881% 2.651% 0.101% 0.166% 0.016% 0.006% - - 0.229% 0.081% 0.004% 0.002% 
20 ± 24 1.800% 2.692% 0.330% 0.161% 0.015% 0.005% - - 0.209% 0.072% 0.022% 0.003% 
25 ± 34 0.704% 0.631% 0.292% 0.055% 0.042% 0.014% - - 0.586% 0.195% 0.036% 0.003% 
35 ± 44 0.205% 0.120% 0.143% 0.015% 0.033% 0.011% - - 0.471% 0.155% 0.035% 0.001% 
45 ± 64 0.057% 0.023% 0.041% 0.004% 0.017% 0.006% - - 0.243% 0.079% 0.014% 0.000% 
65+ 0.006% 0.001% 0.004% 0.000% 0.004% 0.001% - - 0.053% 0.014% 0.001% 0.000% 
MSM 
13 ± 14 0.026% - 0.011% - 0.000% - 0.000% - 0.000% - 0.000% - 
15 ± 19 1.705% - 1.240% - 0.464% - 4.732% - 8.605% - 0.088% - 
20 ± 24 5.911% - 6.548% - 0.424% - 4.321% - 7.859% - 0.629% - 
25 ± 34 5.595% - 7.539% - 1.241% - 12.657% - 23.019% - 1.116% - 
35 ± 44 3.443% - 4.101% - 0.728% - 7.421% - 13.496% - 1.104% - 
45 ± 64 1.125% - 1.113% - 0.311% - 3.175% - 5.774% - 0.435% - 
65+ 0.124% - 0.081% - 0.030% - 0.305% - 0.554% - 0.026% - 
BLACK ETHNIC MINORITIES 
13 ± 14 0.015% 0.231% 0.003% 0.028% 0.231% 0.641% 0.284% 0.759% 0.369% 0.881% 0.000% 0.000% 
15 ± 19 1.491% 4.485% 0.286% 0.469% 0.987% 2.752% 1.214% 3.261% 1.579% 3.784% 0.006% 0.003% 
20 ± 24 3.044% 4.554% 0.932% 0.454% 0.901% 2.457% 1.108% 2.911% 1.442% 3.378% 0.037% 0.005% 
25 ± 34 1.192% 1.067% 0.826% 0.157% 2.524% 6.634% 3.105% 7.861% 4.039% 9.122% 0.061% 0.005% 
35 ± 44 0.346% 0.203% 0.403% 0.041% 2.026% 5.297% 2.492% 6.277% 3.242% 7.283% 0.060% 0.002% 
45 ± 64 0.096% 0.039% 0.117% 0.010% 1.046% 2.696% 1.287% 3.195% 1.674% 3.707% 0.024% 0.001% 
65+ 0.010% 0.001% 0.011% 0.000% 0.228% 0.492% 0.280% 0.583% 0.364% 0.676% 0.002% 0.000% 
Table 3 Results of modelling the C-card program in young people for the whole eligible population of England 
Scenario STIs averted STI cost 
savings 
Program 
cost 
Net cost QALY 
gain 
Cost/QALY 
 Chlamydia Gonorrhoea HIV Syphilis PID Total  
Base case (age 13-24) 4272 378 6 14 454 5123 £2,587,340 £3,544,962 £957,622 55 £17,411 
1: Age 13-18 1151 83 2 2 135 1373 £758,947 £1,538,499 £779,552 17 £45,856 
2: Lower RR condom use 2007 178 3 7 215 2409 £1.216.794 £3,530,260 £2,313,466 26 £88,979 
3: Breakage reduced 4586 407 5 15 487 5501 £2,728,775 £3,539,033 £810,258 56 £14,468 
4: High HIV prevalence 4254 376 77 14 454 5174 £9,954,650 £3,541,896 -£6,412,754 496 Dominates 
 
 
Figure 1 Threshold analyses showing cost per QALY gained from the base-case analysis across a range of 
program costs (per person per annum) and effectiveness levels (relative risk of condom use) in a) young people 
b) MSM c) black ethnic minorities and d) general population 
 
  
Figure 2: Validation results 
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